Bone Biologics Corp financial data

Symbol
BBLG, BBLGW on Nasdaq
Location
2 Burlington Woods Drive,, Suite 100,, Burlington, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.38K %
Debt-to-equity 7.8 % -58%
Return On Equity -101 % +34.8%
Return On Assets -93.3 % +28.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.8M shares -0.34%
Common Stock, Shares, Outstanding 1.69M shares +28.1%
Entity Public Float 1.57M USD -62.4%
Common Stock, Value, Issued 1.69K USD +28.1%
Weighted Average Number of Shares Outstanding, Basic 558K shares +186%
Weighted Average Number of Shares Outstanding, Diluted 558K shares +186%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.15M USD -17.9%
General and Administrative Expense 2.14M USD -8.27%
Operating Income (Loss) -4.29M USD +13.4%
Nonoperating Income (Expense) 72.2K USD -70.9%
Net Income (Loss) Attributable to Parent -4.22M USD +17.6%
Earnings Per Share, Basic -1 USD/shares -105%
Earnings Per Share, Diluted -1 USD/shares -105%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.19M USD +6.43%
Assets, Current 7M USD +119%
Assets 7M USD +119%
Liabilities, Current 406K USD +42.8%
Liabilities 406K USD +42.8%
Retained Earnings (Accumulated Deficit) -86.8M USD -5.11%
Stockholders' Equity Attributable to Parent 6.6M USD +127%
Liabilities and Equity 7M USD +119%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -926K USD +28.9%
Net Cash Provided by (Used in) Financing Activities 348K USD -76.9%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 3.27M shares +222%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -579K USD -388%
Deferred Tax Assets, Valuation Allowance 21.7M USD +6.23%
Deferred Tax Assets, Gross 21.7M USD +6.23%
Deferred Tax Assets, Operating Loss Carryforwards 10.8M USD +12.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 93.4M USD +9.25%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%